RIPE Knowledge Graph
RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1136%2Fbmj-2025-084290

https://w3id.org/ripe/ripe-kg/work/10.1136%2Fbmj-2025-084290
SubjectPredicateObject
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:publication-details/RIPEA10E0E50BEC9CF233Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:registry-evidence/RIPEA10E0E50BEC9CF233 ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:registry-evidence/RIPEA10E0E50BEC9CF233 ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233 ripe:assesses ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233 ripe:assesses ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:study-design-evidence/RIPEA10E0E50BEC9CF233 ripe:concerns ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial prism:doi 10.1136/bmj-2025-084290
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies prism:doi 10.1136/bmj-2025-084290
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU1B2491EA4E65D979Jinhui Ye
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU1B2491EA4E65D979Jinhui Ye
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU263DFC96A902E6CDChang Gong
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU263DFC96A902E6CDChang Gong
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU272888B5D29468ECWei Wei
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU272888B5D29468ECWei Wei
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU451C5DDA905EB669Ailing Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU451C5DDA905EB669Ailing Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU7F6C071402031B3ALehong Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU7F6C071402031B3ALehong Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU94004D0173EFBA6BQiang Liu
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU94004D0173EFBA6BQiang Liu
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAU975A198B3B7005F7Erwei Song
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAU975A198B3B7005F7Erwei Song
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUC35EC5DF79FBD205Fei Xu
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUC35EC5DF79FBD205Fei Xu
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUC588FEBBF901D0EAYingying Zhu
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUC588FEBBF901D0EAYingying Zhu
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUD6C2784FECB8E7EDWeige Tan
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUD6C2784FECB8E7EDWeige Tan
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUD704168328F5B041Yuan Xia
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUD704168328F5B041Yuan Xia
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUDFDE3FFA56078CB8Zouxiang Chen
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUDFDE3FFA56078CB8Zouxiang Chen
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUEBE9725609203003Jun Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUEBE9725609203003Jun Zhang
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUECE898067B674082Yaping Yang
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUECE898067B674082Yaping Yang
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:creator ripekg:author/RIPEAUEE2532D5A78A94E1Li Ling
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:creator ripekg:author/RIPEAUEE2532D5A78A94E1Li Ling
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:title Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:title Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial dcterms:title Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies dcterms:title Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjama.2018.19323Breast cancer treatment: a review
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjama.2018.19323Breast cancer treatment: a review
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjama.2020.23370Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjama.2020.23370Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjamaoncol.2017.1269Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1001%2Fjamaoncol.2017.1269Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fbf00216925Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fbf00216925Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fs00520-010-0851-8et alSkin care management in cancer patients: an evaluation of quality of life and tolerability
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fs00520-010-0851-8et alSkin care management in cancer patients: an evaluation of quality of life and tolerability
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2F0014-2999%2893%2990925-8Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2F0014-2999%2893%2990925-8Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2F0304-3940%2894%2990272-0Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2F0304-3940%2894%2990272-0Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.annonc.2020.11.005. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.annonc.2020.11.005. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ejca.2003.12.004Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ejca.2003.12.004Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ejca.2017.02.024Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ejca.2017.02.024Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.expneurol.2009.12.017Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.expneurol.2009.12.017Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.jaad.2014.03.019Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.jaad.2014.03.019Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejm199504063321401Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejm199504063321401Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejmoa1612645Adjuvant capecitabine for breast cancer after preoperative chemotherapy
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejmoa1612645Adjuvant capecitabine for breast cancer after preoperative chemotherapy
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1080%2F01635581.202A systematic review of the benefit of B-vitamins as a complementary treatment in cancer patients
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1080%2F01635581.202A systematic review of the benefit of B-vitamins as a complementary treatment in cancer patients
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fannonc%2Fmdr400Celecoxib can prevent capecitabinerelated hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fannonc%2Fmdr400Celecoxib can prevent capecitabinerelated hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fjnci%2F85.5.365The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fjnci%2F85.5.365The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1097%2F01.cnd.0000211401.19995.a2Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1097%2F01.cnd.0000211401.19995.a2Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fj.1365-2125.2008.03159.xCandidate mechanisms for capecitabine-related hand-foot syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fj.1365-2125.2008.03159.xCandidate mechanisms for capecitabine-related hand-foot syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1155%2F2013%2F424651Methylcobalamin: a potential vitamin of pain killer
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1155%2F2013%2F424651Methylcobalamin: a potential vitamin of pain killer
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1177%2F014107680609900315Risk of cardiovascular events and celecoxib: a systematic review and metaanalysis
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1177%2F014107680609900315Risk of cardiovascular events and celecoxib: a systematic review and metaanalysis
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1177%2F10781552231178686et alSafety and efficacy of vitamin B in cancer treatments: a systematic review
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1177%2F10781552231178686et alSafety and efficacy of vitamin B in cancer treatments: a systematic review
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.19.00647Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.19.00647Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.19.01203Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221)
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.19.01203Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221)
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.1996.14.10.2756The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.1996.14.10.2756The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2007.15.2090Potential regional differences for the tolerability profiles of fluoropyrimidines
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2007.15.2090Potential regional differences for the tolerability profiles of fluoropyrimidines
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2010.29.9859Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2010.29.9859Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2014.60.4587Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2014.60.4587Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.23.01730D-TORCH Trial Investigators. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: a double-blind randomized controlled trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.23.01730D-TORCH Trial Investigators. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: a double-blind randomized controlled trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.24.00938Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1517%2F13543784.17.6.953
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1517%2F13543784.17.6.953
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1634%2Ftheoncologist.2011-0033HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1634%2Ftheoncologist.2011-0033HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.1634%2Ftheoncologist.2014-0219The Hand-Foot Skin Reaction and Quality of Life Questionnaire: an assessment tool for oncology
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.1634%2Ftheoncologist.2014-0219The Hand-Foot Skin Reaction and Quality of Life Questionnaire: an assessment tool for oncology
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.3390%2Fnu13020395Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.3390%2Fnu13020395Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/10.7326%2F0003-4819-111-8-688Pyridoxine for the palmar-plantar erythrodysesthesia syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/10.7326%2F0003-4819-111-8-688Pyridoxine for the palmar-plantar erythrodysesthesia syndrome
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/RIPEW15FC2CC6DD9A971CThe hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/RIPEW15FC2CC6DD9A971CThe hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/RIPEW32F548490F96AFE4Draft Guidance on Diclofenac Sodium
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/RIPEW32F548490F96AFE4Draft Guidance on Diclofenac Sodium
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial http://purl.org/spar/cito/cites ripekg:work/RIPEWB274E75E3115B802Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies http://purl.org/spar/cito/cites ripekg:work/RIPEWB274E75E3115B802Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type node1
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type node1
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type rdfs:Resource
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type rdfs:Resource
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type owl:Thing
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type owl:Thing
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type prov:Entity
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type prov:Entity
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial rdf:type ripe:WorkWork
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies rdf:type ripe:WorkWork
ripekg:work/10.1136%2Fbmj-2025-084290Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial owl:sameAs https://semopenalex.org/work/W4414123033
ripekg:work/10.1136%2Fbmj-2025-084290Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies owl:sameAs https://semopenalex.org/work/W4414123033